Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013

BACKGROUND: Tumor testing for mutations in the epidermal growth factor receptor (EGFR) gene is indicated for all newly diagnosed, metastatic lung cancer patients, who may be candidates for first-line treatment with an EGFR tyrosine kinase inhibitor. Few studies have analyzed population-level testing...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Julie A., Berse, Brygida, Rabb, Merry, Mosquin, Paul, Chew, Rob, West, Suzanne L., Coomer, Nicole, Becker, Daniel, Kautter, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859516/
https://www.ncbi.nlm.nih.gov/pubmed/29554880
http://dx.doi.org/10.1186/s12885-018-4190-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859516/
https://www.ncbi.nlm.nih.gov/pubmed/29554880
http://dx.doi.org/10.1186/s12885-018-4190-3

Ejemplares similares